A previous in vitro investigation found that a sinergistic effect might occur, when using itraconazole (ITRA) and ritonavir (RTV) against Histoplasma capsulatum, 1 where an interesting mechanism of action was proposed. However, relevant pharmacokinetic (PK) issues were under explored. Herein, this letter attempts to deepen a clinical PK discussion not performed by Brilhante and colleagues. 1 Firstly, the in vitro model 1 did not account for drug penetration in macrophages, given that Histoplasma spp. are found as intracellular microorganisms after innate immunity recognition and phagocytation. 2 Secondly, one should recognize the potential CYP3A4 competitive inhibition when using RTV and an azolic agent. By combining them, we expect an elevated plasma concentration of the azolic agent, 3 as RTV has higher affinity to the aforementioned phase 1 enzyme, but not the opposite. 1 The association of both drugs is a possible scenario 4 when treating multiple drug resistant HIV infected patients. Whether non-CYP3A4 substrates are unavailable, clinicians should attempt to monitoring hepatic enzymes and random ITRA steady state serum concentrations (>1 g/mL) after 7-15 days. 3 Finally, the previous report 1 discussed that using both drugs might be clinically possible by "reducing itraconazole dose". For several reasons, 5 there is no evidence on lowering ITRA doses: (a) it has an erratic gastrointestinal absorption and food composition and gastric pH might influence drug's bioavailability (cyclodextrin-containing formulations are preferred); (b) ITRA has non-linear PK, thus, dose reductions may lead to unpredictable serum levels (zero order kinetics is dependent on enzyme saturation).
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